Role of Suzetrigine as a Part of a Multimodal Regimen to Reduce Pain and Opioid Use After Total Knee Arthroplasty

Inclusion Criteria: * Patients undergoing primary total knee arthroplasty for osteoarthritis of the knee. * Patients between the ages of 18 and 95 years. Exclusion Criteria: * Patients with concurrent and significant injuries to other bones or organs. * Patients with local infections. * Minors unable to provide informed consent for participation in the study. * Subjects who, in the opinion of the investigator, may be non-compliant with study schedules or procedures. * Patients with pre-existing immune suppression, where further immune suppression with GCs could warrant unwarranted or unneeded risk. * Patients with preoperative opioid use, defined as daily use less than 4 weeks before the index surgery. * Patients with a history of severe heart disease (NYHA2), renal failure, or liver dysfunction * Patients with active peptic ulcer disease. * Patients neurological or psychiatric diseases, potentially influencing pain perception * Patients who are pregnant. * Patients with a history of alcohol or medical abuse, allergies to glucocorticoids, current daily use of glucocorticoids. * Patients who are unable to take NSAIDs. * Patients who receive Deep Venous Thrombosis (DVT) prophylaxis different than Aspirin (81mg) twice daily (BID). * Patients who have known diabetes mellitus as defined with an A1C greater than 6.5%. * Patients currently taking CYP3A inhibitors